TY - JOUR AU - Ferlay, J. AU - Soerjomataram, I. AU - Dikshit, R. AU - Eser, S. AU - Mathers, C. AU - Rebelo, M. PY - 2015 DA - 2015// TI - Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 JO - Int J Cancer VL - 136 UR - https://doi.org/10.1002/ijc.29210 DO - 10.1002/ijc.29210 ID - Ferlay2015 ER - TY - JOUR AU - Mazzone, P. AU - Mekhail, T. PY - 2012 DA - 2012// TI - Current and emerging medical treatments for non-small cell lung cancer: a primer for pulmonologists JO - Respir Med VL - 106 UR - https://doi.org/10.1016/j.rmed.2011.10.016 DO - 10.1016/j.rmed.2011.10.016 ID - Mazzone2012 ER - TY - JOUR AU - Kobayashi, S. AU - Boggon, T. J. AU - Dayaram, T. AU - Janne, P. A. AU - Kocher, O. AU - Meyerson, M. PY - 2005 DA - 2005// TI - EGFR mutation and resistance of non-small-cell lung cancer to gefitinib JO - N Engl J Med VL - 352 UR - https://doi.org/10.1056/NEJMoa044238 DO - 10.1056/NEJMoa044238 ID - Kobayashi2005 ER - TY - JOUR AU - Morgan, R. A. AU - Dudley, M. E. AU - Wunderlich, J. R. AU - Hughes, M. S. AU - Yang, J. C. AU - Sherry, R. M. PY - 2006 DA - 2006// TI - Cancer regression in patients after transfer of genetically engineered lymphocytes JO - Science VL - 314 UR - https://doi.org/10.1126/science.1129003 DO - 10.1126/science.1129003 ID - Morgan2006 ER - TY - JOUR AU - Schuster, M. AU - Nechansky, A. AU - Kircheis, R. PY - 2006 DA - 2006// TI - Cancer immunotherapy JO - Biogeosciences VL - 1 ID - Schuster2006 ER - TY - JOUR AU - Gabrilovich, D. I. AU - Nagaraj, S. PY - 2009 DA - 2009// TI - Myeloid-derived suppressor cells as regulators of the immune system JO - Nat Rev Immunol VL - 9 UR - https://doi.org/10.1038/nri2506 DO - 10.1038/nri2506 ID - Gabrilovich2009 ER - TY - JOUR AU - Zitvogel, L. AU - Apetoh, L. AU - Ghiringhelli, F. AU - André, F. AU - Tesniere, A. AU - Kroemer, G. PY - 2008 DA - 2008// TI - The anticancer immune response: indispensable for therapeutic success? JO - Clin Invest VL - 118 UR - https://doi.org/10.1172/JCI35180 DO - 10.1172/JCI35180 ID - Zitvogel2008 ER - TY - JOUR AU - Liu, Y. AU - Zeng, G. PY - 2012 DA - 2012// TI - Cancer and innate immune system interactions: translational potentials for cancer immunotherapy JO - Immunother VL - 35 UR - https://doi.org/10.1097/CJI.0b013e3182518e83 DO - 10.1097/CJI.0b013e3182518e83 ID - Liu2012 ER - TY - JOUR AU - Clark, W. H. AU - Elder, D. E. AU - Guerry, D. AU - Braitman, L. E. AU - Trock, B. J. AU - Schultz, D. PY - 1989 DA - 1989// TI - Model predicting survival in stage I melanoma based on tumor progression JO - Natl Cancer Inst VL - 81 UR - https://doi.org/10.1093/jnci/81.24.1893 DO - 10.1093/jnci/81.24.1893 ID - Clark1989 ER - TY - JOUR AU - Gao, Q. AU - Qiu, S. J. AU - Fan, J. AU - Zhou, J. AU - Wang, X. Y. AU - Xiao, Y. S. PY - 2007 DA - 2007// TI - Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection JO - Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.4565 DO - 10.1200/JCO.2006.09.4565 ID - Gao2007 ER - TY - JOUR AU - Gonzalez-Rodriguez, A. P. AU - Contesti, J. AU - Huergo-Zapico, L. AU - Lopez-Soto, A. AU - Fernandez-Guizan, A. AU - Acebes-Huerta, A. PY - 2010 DA - 2010// TI - Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia JO - Leuk Lymphoma VL - 51 UR - https://doi.org/10.3109/10428194.2010.503820 DO - 10.3109/10428194.2010.503820 ID - Gonzalez-Rodriguez2010 ER - TY - JOUR AU - Mierlo, G. J. AU - Boonman, Z. F. AU - Dumortier, H. M. AU - Boer, A. T. AU - Fransen, M. F. AU - Nouta, J. PY - 2004 DA - 2004// TI - Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication JO - Immunol VL - 173 UR - https://doi.org/10.4049/jimmunol.173.11.6753 DO - 10.4049/jimmunol.173.11.6753 ID - Mierlo2004 ER - TY - JOUR AU - Kurts, C. AU - Robinson, B. W. AU - Knolle, P. A. PY - 2010 DA - 2010// TI - Cross-priming in health and disease JO - Nat Rev Immunol VL - 10 UR - https://doi.org/10.1038/nri2780 DO - 10.1038/nri2780 ID - Kurts2010 ER - TY - JOUR AU - Shresta, S. AU - Pham, C. T. AU - Thomas, D. A. AU - Graubert, T. A. AU - Ley, T. J. PY - 1998 DA - 1998// TI - How do cytotoxic lymphocytes kill their targets? JO - Curr Opin Immunol VL - 10 UR - https://doi.org/10.1016/S0952-7915(98)80227-6 DO - 10.1016/S0952-7915(98)80227-6 ID - Shresta1998 ER - TY - JOUR AU - Cullen, S. P. AU - Martin, S. J. PY - 2008 DA - 2008// TI - Mechanisms of granule-dependent killing JO - Cell Death Differ VL - 15 UR - https://doi.org/10.1038/sj.cdd.4402244 DO - 10.1038/sj.cdd.4402244 ID - Cullen2008 ER - TY - JOUR AU - Cullen, S. P. AU - Brunet, M. AU - Martin, S. J. PY - 2010 DA - 2010// TI - Granzymes in cancer and immunity JO - Cell Death Differ VL - 17 UR - https://doi.org/10.1038/cdd.2009.206 DO - 10.1038/cdd.2009.206 ID - Cullen2010 ER - TY - JOUR AU - Nagata, S. AU - Golstein, P. PY - 1995 DA - 1995// TI - The Fas death factor JO - Science VL - 267 UR - https://doi.org/10.1126/science.7533326 DO - 10.1126/science.7533326 ID - Nagata1995 ER - TY - JOUR AU - Qin, Z. AU - Schwartzkopff, J. AU - Pradera, F. AU - Kammertoens, T. AU - Seliger, B. AU - Pircher, H. AU - Blankenstein, T. PY - 2003 DA - 2003// TI - A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells JO - Cancer Res VL - 63 ID - Qin2003 ER - TY - JOUR AU - Stoelcker, B. AU - Ruhland, B. AU - Hehlgans, T. AU - Bluethmann, H. AU - Luther, T. AU - Mannel, D. N. PY - 2000 DA - 2000// TI - Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature JO - Am J Pathol VL - 156 UR - https://doi.org/10.1016/S0002-9440(10)64986-3 DO - 10.1016/S0002-9440(10)64986-3 ID - Stoelcker2000 ER - TY - JOUR AU - Mosmann, T. R. AU - Coffman, R. L. PY - 1989 DA - 1989// TI - TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties JO - Annu Rev Immunol VL - 7 UR - https://doi.org/10.1146/annurev.iy.07.040189.001045 DO - 10.1146/annurev.iy.07.040189.001045 ID - Mosmann1989 ER - TY - JOUR AU - Sakaguchi, S. PY - 2005 DA - 2005// TI - Naturally arising Foxp3-expressing CD25 + CD4+ regulatory T cells in immunological tolerance to self and non-self JO - Nat Immunol VL - 6 UR - https://doi.org/10.1038/ni1178 DO - 10.1038/ni1178 ID - Sakaguchi2005 ER - TY - JOUR AU - Korn, T. AU - Oukka, M. AU - Kuchroo, V. AU - Bettelli, E. PY - 2007 DA - 2007// TI - Th17 cells: effector T cells with inflammatory properties JO - Semin Immunol VL - 19 UR - https://doi.org/10.1016/j.smim.2007.10.007 DO - 10.1016/j.smim.2007.10.007 ID - Korn2007 ER - TY - JOUR AU - Végran, F. AU - Apetoh, L. AU - Ghiringhelli, F. PY - 2015 DA - 2015// TI - Th9 cells: a novel CD4 T-cell subset in the immune war against cancer JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-14-2748 DO - 10.1158/0008-5472.CAN-14-2748 ID - Végran2015 ER - TY - JOUR AU - Trifari, S. AU - Kaplan, C. D. AU - Tran, E. H. AU - Crellin, N. K. AU - Spits, H. PY - 2009 DA - 2009// TI - Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells JO - Nat Immunol VL - 10 UR - https://doi.org/10.1038/ni.1770 DO - 10.1038/ni.1770 ID - Trifari2009 ER - TY - JOUR AU - Crotty, S. PY - 2011 DA - 2011// TI - Follicular helper CD4 T cells (TFH) JO - Annu Rev Immunol VL - 29 UR - https://doi.org/10.1146/annurev-immunol-031210-101400 DO - 10.1146/annurev-immunol-031210-101400 ID - Crotty2011 ER - TY - JOUR AU - Kim, H. J. AU - Cantor, H. PY - 2014 DA - 2014// TI - CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful JO - Cancer Immunol Res VL - 2 UR - https://doi.org/10.1158/2326-6066.CIR-13-0216 DO - 10.1158/2326-6066.CIR-13-0216 ID - Kim2014 ER - TY - JOUR AU - Bos, R. AU - Sherman, L. A. PY - 2010 DA - 2010// TI - CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-10-1322 DO - 10.1158/0008-5472.CAN-10-1322 ID - Bos2010 ER - TY - JOUR AU - Ikeda, H. AU - Old, L. J. AU - Schreiber, R. D. PY - 2002 DA - 2002// TI - The roles of IFN in protection against tumor development and cancer immunoediting JO - Cytokine Growth Factor Rev VL - 13 UR - https://doi.org/10.1016/S1359-6101(01)00038-7 DO - 10.1016/S1359-6101(01)00038-7 ID - Ikeda2002 ER - TY - JOUR AU - Galaine, J. AU - Borg, C. AU - Godet, Y. AU - Adotévi, O. PY - 2015 DA - 2015// TI - Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine JO - Vaccines VL - 3 UR - https://doi.org/10.3390/vaccines3030490 DO - 10.3390/vaccines3030490 ID - Galaine2015 ER - TY - JOUR AU - Haabeth, O. W. AU - Tveita, A. A. AU - Fauskanger, M. AU - Schjesvold, F. AU - Lorvik, K. B. AU - Hofgaard, P. O. PY - 2014 DA - 2014// TI - How Do CD4+ T cells detect and eliminate tumor cells that either Lack or express MHC class II molecules? JO - Front Immunol VL - 5 UR - https://doi.org/10.3389/fimmu.2014.00174 DO - 10.3389/fimmu.2014.00174 ID - Haabeth2014 ER - TY - JOUR AU - Trapani, J. A. AU - Davis, J. AU - Sutton, V. R. AU - Smyth, M. J. PY - 2000 DA - 2000// TI - Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo JO - Curr Opin Immunol VL - 12 UR - https://doi.org/10.1016/S0952-7915(00)00094-7 DO - 10.1016/S0952-7915(00)00094-7 ID - Trapani2000 ER - TY - JOUR AU - Cretney, E. AU - Takeda, K. AU - Yagita, H. AU - Glaccum, M. AU - Peschon, J. J. AU - Smyth, M. J. PY - 2002 DA - 2002// TI - Increased susceptibility to tumor initiation and metastasis in TNFrelated apoptosis-inducing ligand-deficient mice JO - Immunol VL - 168 UR - https://doi.org/10.4049/jimmunol.168.3.1356 DO - 10.4049/jimmunol.168.3.1356 ID - Cretney2002 ER - TY - JOUR AU - Sutlu, T. AU - Alici, E. PY - 2009 DA - 2009// TI - Natural killer cell-based immunotherapy in cancer: current insights and future prospects JO - Intern Med VL - 266 UR - https://doi.org/10.1111/j.1365-2796.2009.02121.x DO - 10.1111/j.1365-2796.2009.02121.x ID - Sutlu2009 ER - TY - JOUR AU - Smyth, M. J. AU - Hayakawa, Y. AU - Takeda, K. AU - Yagita, H. PY - 2002 DA - 2002// TI - New aspects of natural killer-cell surveillance and therapy of cancer JO - Nat Rev Cancer VL - 2 UR - https://doi.org/10.1038/nrc928 DO - 10.1038/nrc928 ID - Smyth2002 ER - TY - JOUR AU - Vivier, E. AU - Tomasello, E. AU - Baratin, M. AU - Walzer, T. AU - Ugolini, S. PY - 2008 DA - 2008// TI - Functions of natural killer cells JO - Nat Immunol VL - 9 UR - https://doi.org/10.1038/ni1582 DO - 10.1038/ni1582 ID - Vivier2008 ER - TY - JOUR AU - Martin-Fontecha, A. AU - Thomsen, L. L. AU - Brett, S. AU - Gerard, C. AU - Lipp, M. AU - Lanzavecchia AU - Sallusto, F. PY - 2004 DA - 2004// TI - Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming JO - Nat Immunol VL - 5 UR - https://doi.org/10.1038/ni1138 DO - 10.1038/ni1138 ID - Martin-Fontecha2004 ER - TY - JOUR AU - Wu, J. AU - Lanier, L. L. PY - 2003 DA - 2003// TI - Natural killer cells and cancer JO - Adv Cancer Res VL - 90 UR - https://doi.org/10.1016/S0065-230X(03)90004-2 DO - 10.1016/S0065-230X(03)90004-2 ID - Wu2003 ER - TY - JOUR AU - Gardai, S. J. AU - Bratton, D. L. AU - Ogden, C. A. AU - Henson, P. M. PY - 2006 DA - 2006// TI - Recognition ligands on apoptotic cells: a perspective JO - Leukoc Biol VL - 79 UR - https://doi.org/10.1189/jlb.1005550 DO - 10.1189/jlb.1005550 ID - Gardai2006 ER - TY - JOUR AU - Jeannin, P. AU - Jaillon, S. AU - Delneste, Y. PY - 2008 DA - 2008// TI - Pattern recognition receptors in the immune response against dying cells JO - Curr Opin Immunol VL - 20 UR - https://doi.org/10.1016/j.coi.2008.04.013 DO - 10.1016/j.coi.2008.04.013 ID - Jeannin2008 ER - TY - JOUR AU - Wyckoff, J. B. AU - Wang, Y. AU - Lin, E. Y. AU - Li, J. F. AU - Goswami, S. AU - Stanley, E. R. PY - 2007 DA - 2007// TI - Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-1823 DO - 10.1158/0008-5472.CAN-06-1823 ID - Wyckoff2007 ER - TY - JOUR AU - Kryczek, I. AU - Zou, L. AU - Rodriguez, P. AU - Zhu, G. AU - Wei, S. AU - Mottram, P. PY - 2006 DA - 2006// TI - B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma JO - Exp Med VL - 203 UR - https://doi.org/10.1084/jem.20050930 DO - 10.1084/jem.20050930 ID - Kryczek2006 ER - TY - JOUR AU - Prehn, R. T. PY - 1970 DA - 1970// TI - Analysis of antigenic heterogeneity within individual 3-methylcholanthrene-induced mouse sarcomas JO - Natl Cancer Inst VL - 45 ID - Prehn1970 ER - TY - JOUR AU - Wortzel, R. D. C. AU - Philipps, H. S. PY - 1983 DA - 1983// TI - Multiple tumor-specific antigens expressed on a single tumour cell JO - Nature VL - 304 UR - https://doi.org/10.1038/304165a0 DO - 10.1038/304165a0 ID - Wortzel1983 ER - TY - JOUR AU - Oleinika, K. AU - Nibbs, R. J. AU - Graham, G. J. AU - Fraser, A. R. PY - 2013 DA - 2013// TI - Suppression, subversion and escape: the role of regulatory T cells in cancer progression JO - Clin Exp Immunol VL - 171 UR - https://doi.org/10.1111/j.1365-2249.2012.04657.x DO - 10.1111/j.1365-2249.2012.04657.x ID - Oleinika2013 ER - TY - JOUR AU - Matsushita, H. AU - Vesely, M. D. AU - Koboldt, D. C. AU - Rickert, C. G. AU - Uppaluri, R. AU - Magrini, V. J. PY - 2012 DA - 2012// TI - Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting JO - Nature VL - 482 UR - https://doi.org/10.1038/nature10755 DO - 10.1038/nature10755 ID - Matsushita2012 ER - TY - JOUR AU - Derniame, S. AU - Vignaud, J. M. AU - Faure, G. C. AU - Bene, M. C. PY - 2008 DA - 2008// TI - Alteration of the immunological synapse in lung cancer: a microenvironmental approach JO - Clin Exp Immunol VL - 154 UR - https://doi.org/10.1111/j.1365-2249.2008.03727.x DO - 10.1111/j.1365-2249.2008.03727.x ID - Derniame2008 ER - TY - JOUR AU - Kida, H. AU - Ihara, S. AU - Kumanogoh, A. PY - 2013 DA - 2013// TI - Involvement of STAT3 in immune evasion during lung tumorigenesis JO - Oncoimmunology VL - 2 UR - https://doi.org/10.4161/onci.22653 DO - 10.4161/onci.22653 ID - Kida2013 ER - TY - JOUR AU - Salmon, H. AU - Donnadieu, E. PY - 2012 DA - 2012// TI - Within tumors, interactions between T cells and tumor cells are impeded by the extracellular matrix JO - Oncoimmunology VL - 1 UR - https://doi.org/10.4161/onci.20239 DO - 10.4161/onci.20239 ID - Salmon2012 ER - TY - JOUR AU - Ramnath, N. AU - Tan, D. AU - Li, Q. AU - Hylander, B. L. AU - Bogner, P. AU - Ryes, L. AU - Ferrone, S. PY - 2006 DA - 2006// TI - Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? JO - Cancer Immunol Immunother VL - 55 UR - https://doi.org/10.1007/s00262-005-0085-7 DO - 10.1007/s00262-005-0085-7 ID - Ramnath2006 ER - TY - JOUR AU - Woo, E. Y. AU - Yeh, H. AU - Chu, C. S. AU - Schlienger, K. AU - Carroll, R. G. AU - Riley, J. L. PY - 2002 DA - 2002// TI - Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation JO - Immunol VL - 168 UR - https://doi.org/10.4049/jimmunol.168.9.4272 DO - 10.4049/jimmunol.168.9.4272 ID - Woo2002 ER - TY - JOUR AU - Lesokhin, A. M. AU - Hohl, T. M. AU - Kitano, S. AU - Cortez, C. AU - Hirschhorn-Cymerman, D. AU - Avogadri, F. PY - 2012 DA - 2012// TI - Monocytic CCR2+ myeloid-derived suppressor cells promote immune escape by limiting activated CD8 Tcell infiltration into the tumor microenvironment JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-11-1792 DO - 10.1158/0008-5472.CAN-11-1792 ID - Lesokhin2012 ER - TY - JOUR AU - Erfani, N. AU - Mehrabadi, S. M. AU - Ghayumi, M. A. AU - Haghshenas, M. R. AU - Mojtahedi, Z. AU - Ghaderi, A. AU - Amani, D. PY - 2012 DA - 2012// TI - Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC) JO - Lung Cancer VL - 77 UR - https://doi.org/10.1016/j.lungcan.2012.04.011 DO - 10.1016/j.lungcan.2012.04.011 ID - Erfani2012 ER - TY - JOUR AU - Jiang, Y. AU - Li, Y. AU - Zhu, B. PY - 2015 DA - 2015// TI - T-cell exhaustion in the tumor microenvironment JO - Cell Death Dis VL - 6 UR - https://doi.org/10.1038/cddis.2015.162 DO - 10.1038/cddis.2015.162 ID - Jiang2015 ER - TY - JOUR AU - Sauce, D. AU - Almeida, J. R. AU - Larsen, M. AU - Haro, L. AU - Autran, B. AU - Freeman, G. J. AU - Appay, V. PY - 2007 DA - 2007// TI - PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status JO - AIDS VL - 21 UR - https://doi.org/10.1097/QAD.0b013e3282eee548 DO - 10.1097/QAD.0b013e3282eee548 ID - Sauce2007 ER - TY - JOUR AU - Liang, S. C. AU - Latchman, Y. E. AU - Buhlmann, J. E. AU - Tomczak, M. F. AU - Horwitz, B. H. AU - Freeman, G. J. AU - Sharpe, A. H. PY - 2003 DA - 2003// TI - Regulation of PD-1, PDL1, and PD-L2 expression during normal and autoimmune responses JO - Eur J Immunol VL - 33 UR - https://doi.org/10.1002/eji.200324228 DO - 10.1002/eji.200324228 ID - Liang2003 ER - TY - JOUR AU - Wölfle, S. J. AU - Strebovsky, J. AU - Bartz, H. AU - Sähr, A. AU - Arnold, C. AU - Kaiser, C. PY - 2011 DA - 2011// TI - PD-L1 expression on tolerogenic APCs is controlled by STAT-3 JO - Eur J Immunol VL - 41 UR - https://doi.org/10.1002/eji.201040979 DO - 10.1002/eji.201040979 ID - Wölfle2011 ER - TY - JOUR AU - Vander Bruggen, P. AU - Traversari, C. AU - Chomez, P. AU - Lurquin, C. AU - Plaen, E. AU - Eynde, B. PY - 1991 DA - 1991// TI - A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma JO - Science VL - 254 UR - https://doi.org/10.1126/science.1840703 DO - 10.1126/science.1840703 ID - Vander Bruggen1991 ER - TY - JOUR AU - Brichard, V. G. AU - Godechal, Q. PY - 2013 DA - 2013// TI - MAGE-A3-specific anticancer immunotherapy in the clinical practice JO - Oncoimmunology VL - 2 UR - https://doi.org/10.4161/onci.25995 DO - 10.4161/onci.25995 ID - Brichard2013 ER - TY - JOUR AU - Vansteenkiste, J. AU - Zielinski, M. AU - Linder, A. AU - Dahabreh, J. AU - Gonzalez, E. E. AU - Malinowski, W. PY - 2013 DA - 2013// TI - Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results JO - Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.43.7103 DO - 10.1200/JCO.2012.43.7103 ID - Vansteenkiste2013 ER - TY - JOUR AU - Vansteenkiste, J. F. AU - Cho, B. C. AU - Vanakesa, T. AU - Pas, T. AU - Zielinski, M. AU - Kim, M. S. PY - 2016 DA - 2016// TI - Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)00099-1 DO - 10.1016/S1470-2045(16)00099-1 ID - Vansteenkiste2016 ER - TY - JOUR AU - Hollingsworth, M. A. AU - Swanson, B. J. PY - 2004 DA - 2004// TI - Mucins in cancer: protection and control of the cell surface JO - Nat Rev Cancer VL - 4 UR - https://doi.org/10.1038/nrc1251 DO - 10.1038/nrc1251 ID - Hollingsworth2004 ER - TY - JOUR AU - Bafna, S. AU - Kaur, S. AU - Batra, S. K. PY - 2010 DA - 2010// TI - Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells JO - Oncogene VL - 29 UR - https://doi.org/10.1038/onc.2010.87 DO - 10.1038/onc.2010.87 ID - Bafna2010 ER - TY - JOUR AU - Tang, C. K. AU - Apostolopoulos, V. PY - 2008 DA - 2008// TI - Strategies used for MUC1 immunotherapy: preclinical studies JO - Expert Rev Vaccines VL - 7 UR - https://doi.org/10.1586/14760584.7.7.951 DO - 10.1586/14760584.7.7.951 ID - Tang2008 ER - TY - JOUR AU - Decoster, L. AU - Wauters, I. AU - Vansteenkiste, J. F. PY - 2012 DA - 2012// TI - Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development JO - Ann Oncol VL - 23 UR - https://doi.org/10.1093/annonc/mdr564 DO - 10.1093/annonc/mdr564 ID - Decoster2012 ER - TY - JOUR AU - Sangha, R. AU - Butts, C. PY - 2007 DA - 2007// TI - L-BLP25: a peptide vaccine strategy in non small cell lung cancer JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-07-0213 DO - 10.1158/1078-0432.CCR-07-0213 ID - Sangha2007 ER - TY - JOUR AU - Xia, W. AU - Wang, J. AU - Xu, Y. AU - Jiang, F. AU - Xu, L. PY - 2014 DA - 2014// TI - L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review JO - Thorac Dis VL - 6 ID - Xia2014 ER - TY - JOUR AU - Palmer, M. AU - Parker, J. AU - Modi, S. AU - Butts, C. AU - Smylie, M. AU - Meikle, A. PY - 2001 DA - 2001// TI - Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer JO - Clin Lung Cancer VL - 3 UR - https://doi.org/10.3816/CLC.2001.n.018 DO - 10.3816/CLC.2001.n.018 ID - Palmer2001 ER - TY - JOUR AU - Butts, C. AU - Murray, N. AU - Maksymiuk, A. AU - Goss, G. AU - Marshall, E. AU - Soulières, D. PY - 2005 DA - 2005// TI - Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer JO - Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.13.011 DO - 10.1200/JCO.2005.13.011 ID - Butts2005 ER - TY - JOUR AU - Butts, C. AU - Maksymiuk, A. AU - Goss, G. AU - Soulieres, D. AU - Marshall, E. AU - Cormier, Y. PY - 2007 DA - 2007// TI - A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis JO - Thorac Oncol VL - 2 UR - https://doi.org/10.1097/01.JTO.0000283139.22682.5e DO - 10.1097/01.JTO.0000283139.22682.5e ID - Butts2007 ER - TY - JOUR AU - Butts, C. AU - Socinski, M. A. AU - Mitchell, P. L. AU - Thatcher, N. AU - Havel, L. AU - Krzakowski, M. PY - 2014 DA - 2014// TI - Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(13)70510-2 DO - 10.1016/S1470-2045(13)70510-2 ID - Butts2014 ER - TY - JOUR AU - Wakefield, L. M. AU - Hill, C. S. PY - 2013 DA - 2013// TI - Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer JO - Nat Rev Cancer VL - 13 UR - https://doi.org/10.1038/nrc3500 DO - 10.1038/nrc3500 ID - Wakefield2013 ER - TY - JOUR AU - Tian, M. AU - Neil, J. R. AU - Schiemann, W. P. PY - 2011 DA - 2011// TI - Transforming growth factor-beta and the hallmarks of cancer JO - Cell Signal VL - 23 UR - https://doi.org/10.1016/j.cellsig.2010.10.015 DO - 10.1016/j.cellsig.2010.10.015 ID - Tian2011 ER - TY - JOUR AU - Drabsch, Y. AU - Dijke, P. PY - 2012 DA - 2012// TI - TGF-beta signalling and its role in cancer progression and metastasis JO - Cancer Metastasis Rev VL - 31 UR - https://doi.org/10.1007/s10555-012-9375-7 DO - 10.1007/s10555-012-9375-7 ID - Drabsch2012 ER - TY - JOUR AU - Jakowlew, S. B. PY - 2006 DA - 2006// TI - Transforming growth factor-beta in cancer and metastasis JO - Cancer Metastasis Rev VL - 25 UR - https://doi.org/10.1007/s10555-006-9006-2 DO - 10.1007/s10555-006-9006-2 ID - Jakowlew2006 ER - TY - JOUR AU - Nemunaitis, J. AU - Dillman, R. O. AU - Schwarzenberger, P. O. AU - Senzer, N. AU - Cunningham, C. AU - Cutler, J. PY - 2006 DA - 2006// TI - Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non–small-cell lung cancer JO - Clin Oncol VL - 10 UR - https://doi.org/10.1200/JCO.2005.05.5335 DO - 10.1200/JCO.2005.05.5335 ID - Nemunaitis2006 ER - TY - JOUR AU - Giaccone, G. AU - Bazhenova, L. A. AU - Nemunaitis, J. AU - Tan, M. E. AU - Ramlau, J. R. AU - Heuvel, M. M. PY - 2015 DA - 2015// TI - A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer JO - Eur J Cancer VL - 51 UR - https://doi.org/10.1016/j.ejca.2015.07.035 DO - 10.1016/j.ejca.2015.07.035 ID - Giaccone2015 ER - TY - JOUR AU - Linggi, B. AU - Carpenter, G. PY - 2006 DA - 2006// TI - ErbB receptors: New insights on mechanisms and biology JO - Trends Cell Biol VL - 16 UR - https://doi.org/10.1016/j.tcb.2006.10.008 DO - 10.1016/j.tcb.2006.10.008 ID - Linggi2006 ER - TY - JOUR AU - Kuykendall, A. AU - Chiappori, A. PY - 2014 DA - 2014// TI - Advanced EGFR mutation-positive Non–small-cell lung cancer: case report, literature review, and treatment recommendations JO - Moffitt Cancer Center VL - 21 ID - Kuykendall2014 ER - TY - JOUR AU - Hirsch, F. R. AU - Varella-García, M. AU - Cappuzzo, F. PY - 2009 DA - 2009// TI - Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer JO - Oncogene VL - 28 UR - https://doi.org/10.1038/onc.2009.199 DO - 10.1038/onc.2009.199 ID - Hirsch2009 ER - TY - JOUR AU - Rusch, V. AU - Baselga, J. AU - Cordon-Cardo, C. AU - Orazem, J. AU - Zaman, M. AU - Hoda, S. PY - 1993 DA - 1993// TI - Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung JO - Cancer Res VL - 53 ID - Rusch1993 ER - TY - JOUR AU - Neninger Vinageras, E. AU - Torre, A. AU - Osorio Rodriguez, M. AU - Catalá Ferrer, M. AU - Bravo, I. AU - Mendoza del Pino, M. PY - 2008 DA - 2008// TI - Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer JO - Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.11.5980 DO - 10.1200/JCO.2007.11.5980 ID - Neninger Vinageras2008 ER - TY - JOUR AU - Limacher, J. M. AU - Quoix, E. PY - 2012 DA - 2012// TI - TG4010 A therapeutic vaccine against MUC1 expressing tumors JO - OncoImmunology VL - 1 UR - https://doi.org/10.4161/onci.19863 DO - 10.4161/onci.19863 ID - Limacher2012 ER - TY - JOUR AU - Agrawal, B. AU - Krantz, M. J. AU - Reddish, M. A. AU - Longenecker, B. M. PY - 1998 DA - 1998// TI - Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 JO - Nat Med VL - 4 UR - https://doi.org/10.1038/nm0198-043 DO - 10.1038/nm0198-043 ID - Agrawal1998 ER - TY - JOUR AU - Quoix, E. AU - Ramlau, R. AU - Westeel, V. AU - Papai, Z. AU - Madroszyk, A. AU - Riviere, A. PY - 2011 DA - 2011// TI - Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial JO - Lancet Oncol VL - 12 UR - https://doi.org/10.1016/S1470-2045(11)70259-5 DO - 10.1016/S1470-2045(11)70259-5 ID - Quoix2011 ER - TY - JOUR AU - Nagorsen, D. AU - Scheibenbogen, C. AU - Marincola, F. M. AU - Letsch, A. AU - Keilholz, U. PY - 2003 DA - 2003// TI - Natural T cell immunity against cancer JO - Clin Cancer Res VL - 9 ID - Nagorsen2003 ER - TY - JOUR AU - Greenwald, R. J. AU - Freeman, G. J. AU - Sharpe, A. H. PY - 2005 DA - 2005// TI - The B7 family revisited JO - Annu Rev Immunol VL - 23 UR - https://doi.org/10.1146/annurev.immunol.23.021704.115611 DO - 10.1146/annurev.immunol.23.021704.115611 ID - Greenwald2005 ER - TY - JOUR AU - Leach, D. R. AU - Krummel, M. F. AU - Allison, J. P. PY - 1996 DA - 1996// TI - Enhancement of antitumor immunity by CTLA-4 blockade JO - Science VL - 271 UR - https://doi.org/10.1126/science.271.5256.1734 DO - 10.1126/science.271.5256.1734 ID - Leach1996 ER - TY - JOUR AU - Funt, S. A. AU - Page, D. B. AU - Wolchok, J. D. AU - Postow, M. A. PY - 2014 DA - 2014// TI - CTLA-4 antibodies: new directions, new combinations JO - Oncology (Williston Park) VL - 28 ID - Funt2014 ER - TY - JOUR AU - Li, L. AU - Chao, Q. G. AU - Ping, L. Z. AU - Xue, C. AU - Xia, Z. Y. AU - Qian, D. AU - Shi-ang, H. PY - 2009 DA - 2009// TI - The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC JO - Cancer Biother Radiopharm VL - 24 UR - https://doi.org/10.1089/cbr.2008.0612 DO - 10.1089/cbr.2008.0612 ID - Li2009 ER - TY - JOUR AU - Lynch, T. J. AU - Bondarenko, I. AU - Luft, A. AU - Serwatowski, P. AU - Barlesi, F. AU - Chacko, R. PY - 2012 DA - 2012// TI - Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study JO - Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.38.4032 DO - 10.1200/JCO.2011.38.4032 ID - Lynch2012 ER - TY - JOUR AU - Zatloukal, P. AU - Heo, D. S. AU - Park, K. AU - Kang, J. AU - Butts, C. AU - Bradford, D. PY - 2009 DA - 2009// TI - Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC) JO - Clin Oncol VL - 27 ID - Zatloukal2009 ER - TY - JOUR AU - Calabrò, L. AU - Morra, A. AU - Fonsatti, E. AU - Cutaia, O. AU - Amato, G. AU - Giannarelli, D. PY - 2013 DA - 2013// TI - Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70381-4 DO - 10.1016/S1470-2045(13)70381-4 ID - Calabrò2013 ER - TY - JOUR AU - Benjamin, C. AU - Creelan, M. D. PY - 2014 DA - 2014// TI - Update on immune checkpoint inhibitors in lung cancer JO - Moffitt Cancer Center VL - 21 ID - Benjamin2014 ER - TY - JOUR AU - Keir, M. E. AU - Butte, M. J. AU - Freeman, G. J. AU - Sharpe, A. H. PY - 2008 DA - 2008// TI - PD-1 and its ligands in tolerance and immunity JO - Annu Rev Immunol VL - 26 UR - https://doi.org/10.1146/annurev.immunol.26.021607.090331 DO - 10.1146/annurev.immunol.26.021607.090331 ID - Keir2008 ER - TY - JOUR AU - Pardoll, D. M. PY - 2012 DA - 2012// TI - The blockade of immune checkpoints in cancer immunotherapy JO - Nat Rev Cancer VL - 12 UR - https://doi.org/10.1038/nrc3239 DO - 10.1038/nrc3239 ID - Pardoll2012 ER - TY - JOUR AU - Ramsay, A. G. PY - 2013 DA - 2013// TI - Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity JO - Br J Haematol VL - 162 UR - https://doi.org/10.1111/bjh.12380 DO - 10.1111/bjh.12380 ID - Ramsay2013 ER - TY - JOUR AU - Barber, D. L. AU - Wherry, E. J. AU - Masopust, D. AU - Zhu, B. AU - Allison, J. P. AU - Sharpe, A. H. PY - 2006 DA - 2006// TI - Restoring function in exhausted CD8 T cells during chronic viral infection JO - Nature VL - 439 UR - https://doi.org/10.1038/nature04444 DO - 10.1038/nature04444 ID - Barber2006 ER - TY - JOUR AU - Francisco, L. M. AU - Salinas, V. H. AU - Brown, K. E. AU - Vanguri, V. K. AU - Freeman, G. J. AU - Kuchroo, V. K. PY - 2009 DA - 2009// TI - PD-L1 regulates the development, maintenance, and function of induced regulatory T cells JO - Exp Med VL - 206 UR - https://doi.org/10.1084/jem.20090847 DO - 10.1084/jem.20090847 ID - Francisco2009 ER - TY - JOUR AU - Gettinger, S. N. AU - Horn, L. AU - Gandhi, L. AU - Spigel, D. R. AU - Antonia, S. J. AU - Rizvi, N. A. PY - 2015 DA - 2015// TI - Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced Non–small-cell lung cancer JO - Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.3708 DO - 10.1200/JCO.2014.58.3708 ID - Gettinger2015 ER - TY - JOUR AU - Rizvi, N. A. AU - Mazières, J. AU - Planchard, D. AU - Stinchcombe, T. E. AU - Dy, G. K. AU - Antonia, S. J. PY - 2015 DA - 2015// TI - Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70054-9 DO - 10.1016/S1470-2045(15)70054-9 ID - Rizvi2015 ER - TY - JOUR AU - Borghaei, H. AU - Paz-Ares, L. AU - Horn, L. AU - Spigel, D. R. AU - Steins, M. AU - Ready, N. E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced nonsquamous Non–small-cell lung cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1507643 DO - 10.1056/NEJMoa1507643 ID - Borghaei2015 ER - TY - JOUR AU - Garon, E. B. AU - Rizvi, N. A. AU - Hui, R. AU - Leighl, N. AU - Balmanoukian, A. S. AU - Eder, J. P. PY - 2015 DA - 2015// TI - Pembrolizumab for the treatment of non-small-cell lung cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1501824 DO - 10.1056/NEJMoa1501824 ID - Garon2015 ER - TY - JOUR AU - Rizvi, N. AU - Garon, E. AU - Patnaik, A. AU - Gandhi, L. AU - Leighl, N. AU - Balmanoukian, A. PY - 2014 DA - 2014// TI - Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) JO - Clin Oncol VL - 32 ID - Rizvi2014 ER - TY - JOUR AU - Gettinger, S. AU - Shepherd, F. AU - Antonia, S. AU - Brahmer, J. AU - Chow, L. AU - Juergens, R. PY - 2014 DA - 2014// TI - First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status JO - Clin Oncol VL - 32 ID - Gettinger2014 ER - TY - JOUR AU - Soria, J. C. AU - Cruz, C. AU - Bahleda, R. AU - Delord, J. P. AU - Horn, L. AU - Herbst, R. S. PY - 2013 DA - 2013// TI - Clinical activity, safety, and biomarkers of a PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1) JO - Eur J Cancer VL - 49 ID - Soria2013 ER - TY - JOUR AU - Spigel, D. R. AU - Gettinger, S. N. AU - Horn, L. AU - Herbst, R. S. AU - Gandhi, L. AU - Gordon, M. S. PY - 2013 DA - 2013// TI - Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) JO - Clin Oncol VL - 31 ID - Spigel2013 ER - TY - STD TI - Besse B, Johnson M, Jänne PA. Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). Presented at: 2015 European Cancer Congress; September 25–29; Vienna, Austria. Abstract 16LBA. ID - ref107 ER - TY - JOUR AU - Fehrenbacher, L. AU - Spira, A. AU - Ballinger, M. AU - Kowanetz, M. AU - Vansteenkiste, J. AU - Mazieres, J. PY - 2016 DA - 2016// TI - Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(16)00587-0 DO - 10.1016/S0140-6736(16)00587-0 ID - Fehrenbacher2016 ER - TY - JOUR AU - Brahmer, J. R. AU - Tykodi, S. S. AU - Chow, L. Q. AU - Hwu, W. J. AU - Topalian, S. L. AU - Hwu, P. PY - 2012 DA - 2012// TI - Safety and activity of anti-PD-L1 antibody in patients with advanced cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1200694 DO - 10.1056/NEJMoa1200694 ID - Brahmer2012 ER - TY - JOUR AU - Antonia, S. AU - Rizvi, N. AU - Brahmer, J. AU - Ou, S. H. AU - Khleif, S. N. AU - Hwu, W. J. PY - 2016 DA - 2016// TI - Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC) JO - Cancer Immunol Res VL - 4 UR - https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR15-A047 DO - 10.1158/2326-6074.CRICIMTEATIAACR15-A047 ID - Antonia2016 ER - TY - JOUR AU - Planchard, D. AU - Yokoi, T. AU - McCleod, M. J. AU - Fischer, J. R. AU - Kim, Y. C. AU - Ballas, M. PY - 2016 DA - 2016// TI - A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study JO - Clin Lung Cancer VL - 17 UR - https://doi.org/10.1016/j.cllc.2016.03.003 DO - 10.1016/j.cllc.2016.03.003 ID - Planchard2016 ER -